1. Home
  2. EQX vs VERA Comparison

EQX vs VERA Comparison

Compare EQX & VERA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Equinox Gold Corp.

EQX

Equinox Gold Corp.

HOLD

Current Price

$14.48

Market Cap

10.9B

ML Signal

HOLD

Logo Vera Therapeutics Inc.

VERA

Vera Therapeutics Inc.

HOLD

Current Price

$48.64

Market Cap

1.5B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
EQX
VERA
Founded
2007
2016
Country
Canada
United States
Employees
N/A
N/A
Industry
Precious Metals
Biotechnology: Pharmaceutical Preparations
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.9B
1.5B
IPO Year
N/A
2021

Fundamental Metrics

Financial Performance
Metric
EQX
VERA
Price
$14.48
$48.64
Analyst Decision
Buy
Strong Buy
Analyst Count
1
11
Target Price
$17.00
$76.60
AVG Volume (30 Days)
9.2M
1.4M
Earning Date
02-18-2026
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.11
N/A
Revenue
$2,296,356,000.00
N/A
Revenue This Year
$78.98
N/A
Revenue Next Year
$29.11
N/A
P/E Ratio
$127.31
N/A
Revenue Growth
85.65
N/A
52 Week Low
$5.04
$18.53
52 Week High
$15.10
$56.05

Technical Indicators

Market Signals
Indicator
EQX
VERA
Relative Strength Index (RSI) 56.13 58.17
Support Level $13.32 $45.50
Resistance Level $14.67 $56.05
Average True Range (ATR) 0.56 2.43
MACD -0.08 -1.18
Stochastic Oscillator 65.24 31.28

Price Performance

Historical Comparison
EQX
VERA

About EQX Equinox Gold Corp.

Equinox Gold Corp is a mining company engaged in the operation, acquisition, exploration, and development of mineral properties, with a focus on gold. Equinox Gold has around seven operating gold mines and a clear plan to increase production by advancing the pipeline of growth projects. Geographically, the company operates in the United States, Mexico, and Brazil. The majority of its revenue is generated from Canada.

About VERA Vera Therapeutics Inc.

Vera Therapeutics Inc is a clinical stage biotechnology company. It is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. The company's product candidate is atacicept, a fusion protein self-administered as a subcutaneous injection once weekly that blocks both B lymphocyte stimulator and a proliferation-inducing ligand, which stimulate B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases.

Share on Social Networks: